Alpha lipoamide inhibits diabetic kidney fibrosis via improving mitochondrial function and regulating RXRα expression...

Area of Science:

• Nephrology
• Mitochondrial Biology
• Pharmacology

Background:

• Mitochondrial dysfunction is implicated in various kidney diseases.
• Alpha-lipoamide (ALM), a lipoic acid derivative, is known for its antioxidant and mitochondrial-modulating properties.

Purpose of the Study:

• To investigate the potential renal protective effects of alpha-lipoamide (ALM) in a mouse model of type 2 diabetes mellitus (T2DM).
• To elucidate the underlying mechanisms of ALM's protective action in diabetic kidney disease (DKD).

Main Methods:

• 9-week-old db/db mice were treated with ALM (50 mg·kg⁻¹·d⁻¹) for 8 weeks.
• In vitro studies used rat renal tubular epithelial cells (NRK-52E) cultured in high-glucose medium and treated with ALM (200 μM).
• Computational methods (Autodock Vina, PROMO Database) were used to predict molecular targets and interactions.

Main Results:

• ALM administration improved renal function and significantly reduced kidney fibrosis in db/db mice without affecting blood glucose levels.
• ALM ameliorated mitochondrial dysfunction and tubulointerstitial fibrotic lesions, increasing CDX2 and CFTR expression while decreasing β-catenin and Snail.
• In vitro, ALM protected renal tubular epithelial cells from high-glucose-induced injury.
• ALM was predicted to activate Retinoid X receptor-alpha (RXRα), which upregulates CDX2 expression, thereby inhibiting high glucose-mediated injury.

Conclusions:

• Alpha-lipoamide (ALM) demonstrates significant renoprotective effects in a type 2 diabetes mellitus mouse model.
• ALM alleviates diabetic kidney disease by improving mitochondrial function and regulating the CDX2/CFTR/β-catenin signaling axis via RXRα activation.
• ALM represents a promising therapeutic agent for managing diabetic kidney disease.